2021-11-02-dealroom.co-2021年全球健康和生物科技投资报告（英）_40页_14mb

Global Health & Biotech Investment Update

Overview

• Global healthtech and biotech investment continues to grow significantly, with record funding in 2021.
• Total investment estimates suggest healthtech at around $55–60B and biotech at $45–50B for the year.

Key Trends & Highlights

Growth in Investments

• Unprecedented growth in 2021 with record venture capital investments for both sectors.
• Healthtech saw 61 new unicorns reached $1B valuation; biotech recorded 23 new unicorns.

Investment Distribution

• Investment is diversifying beyond traditional centers; Europe and Asia-Pacific show rapid growth.
• The US and China remain dominant, but other regions like Israel, India, and MENA are growing faster than the leading markets.

Major Themes & Sectors

• Beyond telehealth, interest is growing in digital therapeutics, AI in drug discovery, remote monitoring, genomics, and femtech.
• Femtech shows untapped potential but lacks focus on chronic diseases in larger markets.
• mRNA technology (Modernerna, BioNTech) and CRISPR genome editing represent transformative medical advancements.

Market Expansion and Regulation

• Digital care is evolving beyond initial pandemic-driven adoption into sustained innovation.
• New technologies are enabling more efficient, effective care delivery globally.

Future Outlook

• Expectations are high for ongoing advancements driven by AI and technological integration.
• Greater focus on prevention and chronic disease management is anticipated as healthcare spending models evolve.

Geographical Innovation

• European startups saw a 2.0x growth in VC investment in healthtech in 2021; other regions in the MENA and Asia-Pacific showing particular dynamism.

This detailed update provides insights into the current state and future trajectory of investment across major innovation areas within health and biotech.